Intraarterial thrombolytics as an adjunct to mechanical thrombectomy in patients with basilar artery occlusion.

Abstract

There are limited data regarding safety and effectiveness of concurrent intraarterial thrombolytics as adjunct to mechanical thrombectomy in acute ischemic stroke patients with basilar artery occlusion. We analyzed data from a prospective multicenter registry to assess the independent effect of intraarterial thrombolysis on (1) favorable outcome (modified Rankin Scale 0-3) at 90 days; (2) symptomatic intracranial hemorrhage (sICH) within 72 hours; and (3) death within 90days post-enrollment after adjustment for potential confounders. There was no difference in the adjusted odds of achieving favorable outcome at 90 days (odds ratio [OR]=1.1, 95% confidence interval [CI]: 0.73-1.68) in patients who received intraarterial thrombolysis (n=126) compared with those who did not receive intraarterial thrombolysis (n=1546) despite significantly higher use in patients with postprocedure modified Thrombolysis in Cerebral Infarction (mTICI) grade <3. There were no differences in adjusted odds of sICHwithin72hours (OR=0.8, 95% CI: 0.31-2.08) or death within 90days (OR=0.91, 95% CI: 0.60-1.37). In subgroup analyses, intraarterial thrombolysis was associated with (nonsignificantly) higher odds of achieving a favorable outcome at 90days among patients aged between 65 and 80years, those with National Institutes of Health Stroke Scale score <10, and those with postprocedure mTICI grade 2b. Our analysis supported the safety of intraarterial thrombolysis as adjunct to mechanical thrombectomy in acute ischemic stroke patients with basilar artery occlusion. Identification of patient subgroups in whom intraarterial thrombolytics appeared to be more beneficial may assist in future clinical trial designs.